Drug profile · INN
narsoplimab-wuug
YARTEMLEA
narsoplimab-wuug (YARTEMLEA) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — narsoplimab-wuug
- US status
- approved
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
narsoplimab-wuug (YARTEMLEA) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
Key facts
INN narsoplimab-wuug
Brand YARTEMLEA
Formulation INJECTION
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is narsoplimab-wuug?
narsoplimab-wuug (YARTEMLEA) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
What is the brand name for narsoplimab-wuug?
YARTEMLEA is a marketed brand name for narsoplimab-wuug. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of narsoplimab-wuug?
narsoplimab-wuug has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.